Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-22-027826
Filing Date
2022-11-02
Accepted
2022-11-02 16:15:07
Documents
72
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q gthx-20220930.htm   iXBRL 10-Q 1243030
2 EX-10.1 gthx-20220930xex101.htm EX-10.1 379126
3 EX-31.1 gthx-20220930xex311.htm EX-31.1 10617
4 EX-31.2 gthx-20220930xex312.htm EX-31.2 10594
5 EX-32.1 gthx-20220930xex321.htm EX-32.1 5809
6 EX-32.2 gthx-20220930xex322.htm EX-32.2 5459
12 gthx-20220930_g1.jpg GRAPHIC 8623
  Complete submission text file 0001628280-22-027826.txt   6321903

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT gthx-20220930.xsd EX-101.SCH 47684
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT gthx-20220930_cal.xml EX-101.CAL 47224
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT gthx-20220930_def.xml EX-101.DEF 183494
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT gthx-20220930_lab.xml EX-101.LAB 548128
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT gthx-20220930_pre.xml EX-101.PRE 332548
66 EXTRACTED XBRL INSTANCE DOCUMENT gthx-20220930_htm.xml XML 899675
Mailing Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709
Business Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709 919-213-9835
G1 Therapeutics, Inc. (Filer) CIK: 0001560241 (see all company filings)

EIN.: 263648180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38096 | Film No.: 221354273
SIC: 2834 Pharmaceutical Preparations